Amgen (AMGN) says that based upon the recommendation of an independent Data Monitoring Committee, it's terminating its Phase 3 study of its pancreatic cancer drug Ganitumab. After reviewing the pre-planned interim analysis, the committee concluded that the drug was unlikely to demonstrate a statistically significant improvement towards the primary endpoint of overall survival. Shares -0.9% AH.
Are you Bullish or Bearish on ?
Results for ()
Thanks for sharing your thoughts.
From other sites
at Benzinga.com (Thu, 1:25PM)
at Zacks.com (Thu, 11:20AM)
at Benzinga.com (Feb 11, 2015)
at Nasdaq.com (Feb 9, 2015)
at Nasdaq.com (Feb 6, 2015)
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs